NeoGenomics Receives Medicare Coverage for Pantracer Lbx Test Under CMS MolDX Program

lunes, 16 de marzo de 2026, 10:07 am ET1 min de lectura
NEO--

NeoGenomics, a provider of oncology diagnostic testing and consultative services, has received Medicare coverage for its PanTracer Lbx test under the CMS MolDX program. This test is part of the company's range of oncology diagnostic testing services, which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians.

NeoGenomics Receives Medicare Coverage for Pantracer Lbx Test Under CMS MolDX Program

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios